PIK-75 blocks production of PIP2 and/or PIP3, phosphorylation of Akt, and activation of mTORC1 in adipocytes and myotubes. PI 3-kinase (PI3K) catalyzes the synthesis of the second messengers PtdIns-(3)-P, PtdIns-(3,4)-P2, and PtdIns-(3,4,5)-P3. The PI 3-kinase family of enzymes is comprised of 15 members that are divided into three classes according to their structure, substrate specificity, and mode of regulation. In the class I PI 3-kinases, p110α is the primary PI 3-kinase isoform required for insulin signaling in adipocytes and myotubes and is frequently mutated in primary tumors. Small molecule inhibitors of p110α are of interest in cancer treatment research. PIK-75 is an imidazopyridine that selectively inhibits p110α with an IC50 value of 5.8 nM. PIK-75 inhibits p110γ and p110β considerably less effectively.
1 Fan, Q., Knight, Z.A., Goldenberg, D.D., et al. A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell 9 341-349 (2006). 2 Knight, Z.A., Gonzalez, B., Feldman, M.E., et al. A pharmacological map of the PI3-K family defines a role for p110α in insulin signaling. Cell 125 733-747 (2006).
La Santa Cruz Biotechnology, Inc. è un leader mondiale nello sviluppo di prodotti per il mercato della ricerca biomedica. Chiamaci al numero gratuito 1-800-457-3801.
Copyright © 2007-2020 Santa Cruz Biotechnology, Inc. Tutti i diritti riservati. "Santa Cruz Biotechnology", ed il logo Santa Cruz Biotechnology, Inc."Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", il logo San Juan Ranch, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz", ed "EZ Touch" sono marchi registrati dalla Santa Cruz Biotechnology, Inc.
Tutti i marchi sono proprietà dei rispettivi proprietari.